 MENLO PARK, Calif.--BUSINESS WIRE--Personalis, Inc. Nasdaq: PSNL, a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of 150.0 million of its common stock. In addition, Personalis expects to grant the underwriters a 30-day option to purchase up to an additional 22.5 million of common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to 